000153222 001__ 153222 000153222 005__ 20250425150652.0 000153222 0247_ $$2doi$$a10.3390/jcm14041334 000153222 0248_ $$2sideral$$a143685 000153222 037__ $$aART-2025-143685 000153222 041__ $$aeng 000153222 100__ $$aCampos-Sáenz de Santamaría, Amelia$$uUniversidad de Zaragoza 000153222 245__ $$aVExUS protocol along cardiorenal syndrome: An updated review 000153222 260__ $$c2025 000153222 5060_ $$aAccess copy available to the general public$$fUnrestricted 000153222 5203_ $$aHeart failure (HF) is a major cause of hospitalization, often leading to acute kidney injury (AKI) due to venous congestion. The Venous Excess Ultrasound (VExUS) score, introduced by Beaubin-Souligny, is a bedside tool for assessing congestion severity and guiding decongestive therapy. VExUS has demonstrated prognostic value in predicting AKI, HF readmission, and mortality. Indeed, guiding decongestive therapy through the VExUS score has been shown to significantly improve the likelihood of achieving faster decongestion. Objectives: This review aims to discuss the potential role of VExUS and analyze the recent findings about its relevance in guiding decongestive therapy in patients with acute decompensated HF. Methods: A comprehensive literature review was conducted, which identified journal articles focused on VExUS and manual reviews of relevant peer-reviewed journals. Conclusions: VExUS is a promising tool for evaluating venous congestion in cardiorenal patients, thereby improving fluid and diuretic management. It provides real-time, non-invasive monitoring that enhances clinical decision-making. However, its accuracy depends on operator expertise, and further research is needed to validate its application across different patient populations. 000153222 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/ 000153222 655_4 $$ainfo:eu-repo/semantics/review$$vinfo:eu-repo/semantics/publishedVersion 000153222 700__ $$aAlbines Fiestas, Zoila Stany 000153222 700__ $$aCrespo-Aznarez, Silvia 000153222 700__ $$aEsterellas-Sánchez, Laura Karla 000153222 700__ $$0(orcid)0000-0002-2338-7637$$aSánchez-Marteles, Marta$$uUniversidad de Zaragoza 000153222 700__ $$aGarcés-Horna, Vanesa$$uUniversidad de Zaragoza 000153222 700__ $$0(orcid)0000-0002-8328-9836$$aJosa-Laorden, Claudia 000153222 700__ $$0(orcid)0000-0002-0166-2837$$aAlcaine-Otín, Alejandro 000153222 700__ $$0(orcid)0000-0002-6043-4869$$aGiménez-López, Ignacio$$uUniversidad de Zaragoza 000153222 700__ $$0(orcid)0000-0002-4769-7154$$aRubio-Gracia, Jorge$$uUniversidad de Zaragoza 000153222 7102_ $$11012$$2410$$aUniversidad de Zaragoza$$bDpto. Farmac.Fisiol.y Med.L.F.$$cÁrea Fisiología 000153222 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina 000153222 773__ $$g14, 4 (2025), 1334 [11 pp.]$$pJ. clin.med.$$tJournal of Clinical Medicine$$x2077-0383 000153222 8564_ $$s1138565$$uhttps://zaguan.unizar.es/record/153222/files/texto_completo.pdf$$yVersión publicada 000153222 8564_ $$s2600985$$uhttps://zaguan.unizar.es/record/153222/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada 000153222 909CO $$ooai:zaguan.unizar.es:153222$$particulos$$pdriver 000153222 951__ $$a2025-04-25-13:27:34 000153222 980__ $$aARTICLE